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Exploratory analysis of the human 
breast DNA methylation profile 
upon soymilk exposure
Louis Coussement1, Selin Bolca1, Wim Van Criekinge1,2,3, Geert Trooskens1, Klaas Mensaert1, 
Katrien Poels4, Nathalie Roche5, Phillip Blondeel5, Lode Godderis4, Herman Depypere6 & 
Tim De Meyer1,2,3
Upon soy consumption, isoflavone metabolites attain bioactive concentrations in breast tissue possibly 
affecting health. Though in vitro epigenetic activity of soy metabolites has been described, the in 
vivo impact on the epigenome is largely unknown. Therefore, in this case-control study, the breast 
glandular tissue DNA methylome was explored in women undergoing an aesthetic breast reduction. 
After a run-in phase, 10 generally healthy Belgian or Dutch women received soymilk for 5 days. 
MethylCap-seq methylation profiles were compared with those of 10 matched controls. Isoflavones 
and their microbial metabolites were quantified in urine, serum, and glandular breast tissue (liquid 
chromatography-mass spectrometry) and 17β-estradiol in glandular breast tissue (immunoassay). 
Global DNA methylation levels were obtained for 6 cases and 5 controls using liquid chromatography-
mass spectrometry. Although lower MethylCap-seq coverages were observed, mass spectrometry 
results and computational LINE-1 methylation analysis did not provide evidence supporting global 
methylation alterations upon treatment. At a false discovery rate of 0.05, no differentially methylated 
loci were identified. Moreover, a set of previously identified loci was specifically tested, but earlier 
reported results could not be validated. In conclusion, after a 5-day soymilk treatment, no major 
general epigenetic reprogramming in breast tissue could be found in this exploratory study.
Epigenetic mechanisms link genotype with phenotype through reversible DNA modifications. Environmental 
factors, including diet, can remodel our epigenome lifelong in a beneficial or detrimental way1. Whether dietary 
exposure to epigenetically active compounds may result in any, beneficial or adverse, effect remains unclear. In 
particular, dietary exposure to phytoestrogens, a group of non-nutrients capable of interfering with the endog-
enous estrogen signaling and associated processes in vitro and/or in vivo, causes a lot of controversy and safety 
concerns2–4.
Soy is the major dietary source of the isoflavones genistein and daidzein. Upon soymilk consumption, compo-
nents may reach exposure levels in human breast tissue rendering them bioactive5. Epidemiologic data support a 
small reduction in breast cancer risk, though also adverse effects have been reported6,7. Some proteins in soymilk, 
e.g. lunasin, have been attributed tumor suppressor activity, yet particularly isoflavones appear important8.
However, some estrogen receptor-independent mechanisms of action have been postulated, such as attenu-
ation of steroidogenesis and metabolism, as well as regulation of gene expression through epigenetic silencing. 
Indeed, isoflavones, and genistein in particular, have been reported as inhibitors of DNA methyltransferases and 
histone deacetylases9. Data are mainly derived from in vitro experiments measuring the effect of supraphysio-
logical concentrations on single candidate genes whereas results of in vivo studies on dietary isoflavone-induced 
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ID Treatment Age* BMI S Genistein S Daidzein
BG 
Genistein
BG 
Daidzein
BG Total 
Isoflavones
BG 
17β-estradiol
SB1 Soymilk 47 23.88 282.18 175.50 114.04 22.15 136.19 1.38
SB2** Soymilk 52 29.76 1455.61 1184.52 296.24 436.25 732.49 0.45
SB3** Soymilk 20 28.30 246.39 297.95 326.29 369.94 696.23 0.03
SB4 Soymilk 56 28.28 394.22 551.87 169.33 48.88 218.21 0.05
SB5 Control 51 21.50 0.00 0.00 0.00 0.00 0.00 0.06
SB6** Control 18 26.60 0.00 0.00 0.00 0.00 0.00 0.88
SB7 Control 60 31.40 0.00 0.00 0.00 0.00 0.00 0.26
SB8 Soymilk 54 32.95 679.61 583.82 241.88 34.07 275.95 0.10
SB10 Control 57 22.40 0.00 0.00 0.00 0.00 0.00 0.07
SB11 Soymilk 34 24.86 353.05 816.25 194.16 51.10 245.26 0.09
SB12 Control 19 18.70 0.00 0.00 0.00 0.00 0.00 0.02
SB13 Control 52 27.70 0.00 0.00 0.00 0.00 0.00 0.20
SB14** Control 32 25.20 0.00 0.00 0.00 0.00 0.00 0.62
SB15 Control 38 28.60 0.00 0.00 0.00 0.00 0.00 0.02
SB16 Soymilk 52 24.80 283.06 105.14 198.58 54.51 253.09 0.02
SB18 Soymilk 44 23.73 1267.21 1313.52 493.76 666.05 1159.81 1.49
SB19 Soymilk 60 25.32 2831.23 520.10 390.18 67.03 457.21 0.02
SB20 Control 56 24.20 0.00 0.00 0.00 0.00 0.00 0.04
SB21 Control 38 23.20 0.00 0.00 0.00 0.00 0.00 0.86
SB22 Soymilk 18$ 21.48 451.08 1079.20 440.33 369.63 809.96 0.04
Table 1. Subject characteristics. S and BG reflect respectively serum and breast glandular tissue samples. Note: 
samples SB9 and SB17 were technical replicates for MethylCap-seq analysis (see Table 2) and were therefore 
not listed. Units for each variable are: years, kg/m², nmol/L, and pmol/g for respectively the age, BMI, the S 
concentrations and the BG concentrations. *Ages were calculated based on provided birth year and date of 
surgery. Age for one participant (SB22), indicated by $, was manually modified to 18, given that a rounding error 
led to 17 years of age, though no participants were younger than 18 years at the date of procedure. **Smokers.
ID Treatment Coverage Mapped % Mapped Library size
SB1 Soymilk 23641310 15130395 64.00% 3230581
SB2 Soymilk 20005124 13364407 66.80% 2344832
SB3 Soymilk 20596052 13283325 64.49% 3120649
SB4 Soymilk 23605776 16486437 69.84% 2402701
SB5 Control 52472379 36240165 69.07% 4747398
SB6 Control 28784091 19727820 68.54% 2826594
SB7 Control 50403081 34620817 68.69% 4832033
SB8 Soymilk 32235327 22806551 70.75% 3336655
SB9 Control* 30410592 21433945 70.48% NA
SB10 Control 47379658 33209046 70.09% 4353299
SB11 Soymilk 33798425 24635918 72.89% 1859969
SB12 Control 32412829 22138492 68.30% 3408381
SB13 Control 28898463 19854562 68.70% 3212742
SB14 Control 26743842 18134534 67.81% 3319438
SB15 Control 30217735 19679085 65.12% 4302979
SB16 Soymilk 21840292 14934423 68.38% 2837047
SB17 Soymilk* 25667328 18073389 70.41% NA
SB18 Soymilk 24902261 15842246 63.62% 4044801
SB19 Soymilk 28582845 20225632 70.76% 2789297
SB20 Control 29028050 19954925 68.74% 3169451
SB21 Control* 32123694 21969096 68.39% 3446305
SB22 Soymilk* 30182885 20833618 69.02% 2894860
Table 2. MethylCap-seq study characteristics. Columns represent id, coverage (amount of sequenced paired-
end fragments), amount and fraction of mapped fragments, and final library sizes of data used for limma-voom 
statistical analysis. *Technical replicates, replicates with lowest coverage were not considered for statistical 
analysis (therefore “NA” for library size).
www.nature.com/scientificreports/
3SciEntiFic REPORTS |  (2018) 8:13617  | DOI:10.1038/s41598-018-31767-x
epigenetic modifications and related changes in gene expression are still limited. To the best of our knowledge, 
the study of Qin et al.10 is the only report on the effect of dietary isoflavones on the DNA methylation degrees of a 
limited subset (5) of cancer-related genes in human mammary ductoscopy samples. Though no treatment-related 
changes were observed in this study, results suggested an association between higher post-treatment genistein 
levels and RARβ2 (RARB) and CCND2 hypermethylation, which might increase breast cancer risk10.
As epigenetic alterations in breast cancer have been related to histological and outcome data11, additional 
research is required to evaluate the in vivo epigenetic impact of isoflavone exposure in breast tissue, preferably 
in a genome-wide manner. Therefore, here, we explored the breast tissue epigenome of healthy women with and 
without soymilk supplementation, both globally (by liquid chromatography – mass spectrometry, LC-MS) and 
locally (by MethylCap-seq).
Results
Study population. A total of 30 healthy women undergoing an aesthetic breast reduction, all complying with 
the study protocol, participated in this study. However, for the methylomics analysis, 10 controls were selected 
based on their age and menstrual cycle or menopausal status, to match the overall characteristics of subjects in the 
soymilk group. As a result, the sample size was decreased to 20. The age and BMI, based on self-reported weight 
and height measurements, ranged from 17 to 60 y and from 18.7 to 33.0 kg/m², respectively (Table 1). Five women 
(25%; soymilk: 2; control: 3) were in the follicular phase of their menstrual cycle and 3 (15%; soymilk: 2; control: 
1) in the luteal phase, whereas 12 (60%; soymilk: 6; control: 6) were (peri)menopausal. Two women were taking 
oral contraceptives (10%; soymilk: 1; control: 1). All participants reported average fat and fiber intakes, and 4 
women (20%; soymilk: 2; control: 2) were smoking on a daily basis. With regard to past and present isoflavone 
intakes, the study population consisted of mostly non-consumers (80%), with only 2 subjects consuming soy-de-
rived products on a daily-to-weekly basis (soymilk: 1; control: 1).
Exposure to isoflavones and 17β-estradiol. Exposure to genistein, daidzein, and its microbial metab-
olites upon soy supplementation, was assessed as the sum of unconjugated aglycones and deconjugated (sulfo)
glucuronides and sulfates, measured in hydrolyzed urine, serum, and glandular breast tissue. None of the urine 
samples collected at the end of the run-in phase after the intervention phase for the control group contained 
detectable amounts of isoflavones, whereas the estimated daily urinary isoflavone excretion confirmed compli-
ance to the soymilk diet in the treatment group (genistein: 6.6–13,140.0 µmol/day; daidzein: 2.4–2,025.0 µmol/day; 
individual data not shown). Genistein and total daidzein (i.e., sum of daidzein, dihydrodaidzein, 
O-desmethylangolensin, and equol) serum concentrations ranged from 246.4 to 2,831 nmol/L and from 105.1 to 
1,314 nmol/L upon treatment, respectively. In breast glandular tissue, exposure levels of 114.0–493.8 pmol/g genis-
tein, of 22.2–666.0 pmol/g total daidzein, and of 0.021–1.489 pmol/g 17β-estradiol were measured. 17β-estradiol 
was not significantly different between soymilk and control groups (Wilcoxon rank-sum test, P = 0.74). Individual 
hormone and metabolite levels can be found in Table 1.
DNA methylation profiles. Sequencing statistics and data exploration. Overall coverages, amount and 
fraction of mapped fragments, and library sizes upon data summary are shown in Table 2. Hierarchical cluster 
analysis of soy supplementation and control samples revealed that the technical replicates cluster together (Fig. 1), 
yet that there is no major distinction between treated and control subjects. Though the right cluster appears to be 
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Figure 1. Hierarchical cluster analysis of soymilk (S) and control (C) samples based on normalized methylation 
values for 10000 most variable loci (complete linkage, Euclidean distances). Technical replicates are indicated by 
asterisks.
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featured by more soy-treated samples and somewhat lower coverages, no sample characteristic (age, BMI, total 
coverage, library size, treatment) was found to clearly explain these two clusters (data not shown).
Global methylation degrees. Comparison of general sequencing characteristics between the soymilk and con-
trol groups revealed significant differences in coverage (P = 0.009), number of mapped fragments (P = 0.012) 
and library size upon data summary (P = 0.003), despite sample randomization before gDNA extraction and 
MethylCap-seq. The lower coverages for the soymilk samples may suggest global hypomethylation upon soy 
exposure. However, as reflected by the variation in sequencing characteristics for the technical replicates (Table 2), 
technical sequencing variation is an important, yet difficult to assess, confounder. Therefore, we attempted to find 
additional evidence supporting overall differences in DNA methylation between the treatment groups. These 
analyses were based on (i) independent measurement of methylation degree (by LC-MS) on a subset of the pop-
ulation under study, (ii) an evaluation of the association between the MethylCap sequencing characteristics and 
measured soy metabolite concentrations in the tissue for the soy-exposed group only, (iii) evaluation of LINE-1 
methylation (proxy for global methylation12) shifts associated with soy exposure in the MethylCap-seq data (full 
population).
First, for a subset of 6 cases and 5 controls (i.e. 11 subjects of the total of 20), sufficient gDNA was available 
to measure global DNA methylation by LC-MS analysis. No significant difference was observed between cases 
(2.45 ± 0.55%) and controls (2.34 ± 0.46%) (mean ± standard deviation) (P = 0.72).
Next, if sequencing characteristics differ due to soy supplementation, one would expect that these param-
eters are also correlated with the in vivo concentrations of soy metabolites (genistein, total daidzein and total 
isoflavones) in soy treated individuals. However, Spearman correlation revealed no borderline or significant 
associations between MethylCap-seq library size and respectively genistein (ρ = 0.47, P = 0.18), total daidzein 
(ρ = 0.03, P = 0.95), and total isoflavone (ρ = 0.37, P = 0.30) tissue concentrations in those subjects exposed to soy. 
Additionally, the correlations are all positive, opposite of what would be anticipated if soy supplementation would 
lead to global hypomethylation (i.e. lower library sizes with higher isoflavone concentrations). It should be noted 
that the small sample size (n = 10, i.e. only cases) implies a low power.
Finally, LINE-1 repeat methylation was considered, often used as a proxy for “global methylation” levels12. On 
average, approximately 1% of all reads mapped to L1Hs, with no significant differences in LINE-1 methylation 
between both groups (P = 0.49). It should be noted that adjustment for total coverage might have adjusted for the 
total degree of DNA methylation as well. However, it seems unlikely that global hypomethylation equally affects 
all loci in the genome, implying that some (relative) methylation shifts should be observed, cfr. Akalin et al.13. 
Moreover, other relative comparisons, e.g. average genic-intergenic methylation degree ratios, promoter–genic 
methylation degree ratios, revealed no significant differences between treatment groups (data not shown).
Differential DNA methylation. Upon performing the extra filtering steps for minimum coverage, 758,275 var-
iables were withheld for further analysis, leading to the final dataset (see Materials and Methods section). Given 
results from the global DNA methylation analysis, TMM was applied for normalization, assuming that most loci 
are not differentially methylated. At a false discovery rate (FDR) of 0.05, no significant loci were found using 
limma-voom (minimum FDR: 78,9%). The P-value distribution suggests that a minor treatment effect may be 
present in the data (minor enrichment at P = 0, Fig. 2), yet this may also be due to (slightly) imperfect normaliza-
tion of pre-existing library size differences.
Previously, RARB and CCND2 promoter hypermethylation has been associated with in vivo serum genistein 
concentrations10. Moreover, as summarized by Pudenz et al.14, in vitro data suggests an impact of soy isoflavones 
on GSTP1, SCGB3A1 (HIN-1), TERT, BRCA1, BRCA2, ATM, APC, PTEN and SERPINB5 promoter methylation 
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Figure 2. P-value distribution for the general differential methylation analysis.
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and BRCA1 (exon 1) and BRCA2 (exon 2) exon methylation in breast (cancer) cells15. Therefore, we also evalu-
ated differential methylation in these specific regions, except for the BRCA1 and BRCA2 exonic regions where 
coverages were too low to pass the filtering step (see Materials and Methods section). As less putatively methyl-
ated regions (20) were present in these loci compared to the full genome-wide approach, adjustment for multiple 
testing is less conservative. However, still no significant results were found using this approach (minimal FDR: 
36.1%; Table 3).
Furthermore, similar to the analyses by Qin et al.10, Spearman correlation between log-cpm values and resp. 
genistein, total daidizein and total isoflavone concentrations was assessed for these 20 regions in the treatment 
group (Table 4), again without significant results (likewise for Pearson correlations). For RARB, the exact genomic 
region tested by Qin et al.10 was unclear, yet evaluation of other regions in this gene did not yield significant 
results upon FDR adjustment (data not shown). Finally, for completeness, an additional analysis was performed 
for all regions in gene promoters (49,378) given the well-described functional relevance of promoter methylation, 
but also this analysis did not yield significant results (data not shown).
Pathway analysis. Using a P-value cut-off of 0.0005 (see Materials and Methods), Entrez Identifiers of 177 
selected regions were considered for both GO enrichment and KEGG pathway analysis. Using this larger set, top 
GO enrichment results included vacuoles/lysosomes and voltage gated calcium channel gene sets. KEGG path-
way analysis includes involvement of signaling pathways such as mTOR, Oxytocine, MAPK, AGE-RAGE among 
the top results. However, none of these GO terms or KEGG pathways remained significant enriched upon FDR 
adjustment (Top 10 results in Tables 5 and 6).
Discussion
Here, we report the first genome-wide in vivo study on the impact of soymilk consumption on the glandular 
mammary epigenome. The aim of this study, exploratory in nature, was to detect consistent methylation differ-
ences that are specific to exposure to isoflavones by soy intake. Previously reported in vitro experiments1 suggest 
hypomethylation upon soy exposure, which might confer altered breast cancer risk, as reviewed by16. Though 
this study has several limitations (see below), it did not reveal data supporting the latter to be physiologically rel-
evant. Library size estimates appeared to be somewhat lower in the soymilk group, but these estimates are easily 
affected by experimental/technical variation and are, therefore, no reliable proxies for global DNA methylation. 
Moreover, LC-MS analysis of global DNA methylation, association with exposure measures, and MethylCap-seq 
based Line-1 methylation assessment indicated no differences.
Furthermore, locus-specific analysis revealed no significantly differentially methylated loci. Moreover, no sig-
nificant results for RARβ2 and CCND2 could be observed, though Qin et al. linked hypermethylation of these loci 
with genistein serum concentrations10. The latter study reported dose-specific effects of a longer supplementation 
phase (one menstrual cycle vs. 5 days) in a different study population, treated with different sources of isoflavones 
(soy supplements vs. soymilk). Also other previously reported in vitro results14 could not be reproduced, which is 
not so surprising as in vitro findings are often difficult to validate in vivo. Indeed, this is the first genome-wide in 
ID Ensembl ID Gene Symbol logFC t-statistic P-value FDR
40450702 ENSG00000012048 BRCA1 0.601571 2.318641 0.026147 0.361056
41499320 ENSG00000077092 RARB 0.435366 1.918658 0.062905 0.361056
42129392 ENSG00000161055 SCGB3A1 −0.60998 −1.74276 0.089829 0.361056
41919946 ENSG00000164362 TERT 0.460141 1.667295 0.104048 0.361056
39964752 ENSG00000139618 BRCA2 0.35836 1.602313 0.11774 0.361056
40450701 ENSG00000012048 BRCA1 0.471881 1.601995 0.11781 0.361056
42042450 ENSG00000134982 APC −0.55273 −1.52263 0.136503 0.361056
42129390 ENSG00000161055 SCGB3A1 −0.35985 −1.49163 0.144422 0.361056
40582446 ENSG00000206075 SERPINB5 0.362625 1.414938 0.165595 0.365381
40450700 ENSG00000012048 BRCA1 0.332877 1.358449 0.182691 0.365381
42129393 ENSG00000161055 SCGB3A1 −0.24687 −1.15369 0.256156 0.446046
40582443 ENSG00000206075 SERPINB5 −0.30749 −1.1258 0.267628 0.446046
39692687 ENSG00000084207 GSTP1 0.196571 0.806211 0.425363 0.624811
41919949 ENSG00000164362 TERT −0.17685 −0.7853 0.437368 0.624811
40582445 ENSG00000206075 SERPINB5 0.099288 0.421192 0.676094 0.835414
42129391 ENSG00000161055 SCGB3A1 −0.08725 −0.38149 0.705056 0.835414
41919948 ENSG00000164362 TERT −0.10214 −0.37464 0.710102 0.835414
40582447 ENSG00000206075 SERPINB5 −0.06612 −0.29675 0.768347 0.853719
41919950 ENSG00000164362 TERT −0.02402 −0.1002 0.920733 0.928029
40582444 ENSG00000206075 SERPINB5 −0.02584 −0.09095 0.928029 0.928029
Table 3. Previously reported candidate differentially methylated loci upon soy treatment. Columns indicate 
Map of the Human Methylome identifiers, Ensemble id, Gene Symbol, log fold-change (logFC), t-statistic, 
P-value, and False Discovery Rate (FDR).
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vivo study effectively assessing the impact of soymilk on glandular breast tissue, which is the most relevant target 
in the context of breast health. On the other hand, the affinity of MethylCap-seq depends on the sequence context 
of the methylated regions, implying that overall coverage (and therefore power) for some loci might have been 
too limited to validate these known findings17. Nevertheless, previous studies by our group using the same meth-
odology (and often for lower sample sizes) did typically lead to significant results, which were often successfully 
independently validated (e.g. Tomar et al.18, Van Vlodrop et al.19), implying that the applied methodology is a very 
unlikely reason for the general lack of significant findings here.
Yet, as the sample size was relatively small in this exploratory analysis, better powered DNA methylation 
experiments are required to observe potential small effects. Indeed, though this could also be attributed to imper-
fect normalization of observed library size differences, the P-value distribution of the results suggests that such 
minor effects may be present. Moreover, we cannot exclude potential impact on breast cancer risk, be it positive or 
negative. For example, some of the top loci in the general differential methylation analysis, TIAM1, DUSP22 and 
ID Ensembl ID Gene Symbol
Genistein Daidzein Total Isoflavone
ρ P-value FDR ρ P-value FDR ρ P-value FDR
40450702 ENSG00000012048 BRCA1 0.2000 0.5835 0.9457 0.4424 0.2042 0.6184 0.2970 0.4070 0.9608
41919946 ENSG00000164362 TERT 0.0545 0.8916 0.9457 0.4788 0.1661 0.6184 0.1758 0.6320 0.9608
39964752 ENSG00000139618 BRCA2 0.3455 0.3305 0.9457 0.5515 0.1043 0.6184 0.4182 0.2324 0.9608
40450701 ENSG00000012048 BRCA1 0.1394 0.7072 0.9457 0.5273 0.1228 0.6184 0.3333 0.3488 0.9608
40582446 ENSG00000206075 SERPINB5 0.1152 0.7588 0.9457 0.4061 0.2474 0.6184 0.2121 0.5599 0.9608
42129393 ENSG00000161055 SCGB3A1 −0.3212 0.3677 0.9457 −0.5152 0.1328 0.6184 −0.2485 0.4916 0.9608
40582443 ENSG00000206075 SERPINB5 0.3576 0.3128 0.9457 0.4667 0.1782 0.6184 0.3091 0.3871 0.9608
40582445 ENSG00000206075 SERPINB5 −0.2242 0.5367 0.9457 −0.4061 0.2474 0.6184 −0.2727 0.4483 0.9608
41499320 ENSG00000077092 RARB 0.0909 0.8114 0.9457 0.3333 0.3488 0.6783 0.0667 0.8648 0.9608
42129392 ENSG00000161055 SCGB3A1 −0.2606 0.4697 0.9457 −0.2970 0.4070 0.6783 −0.1879 0.6076 0.9608
40582447 ENSG00000206075 SERPINB5 −0.2970 0.4070 0.9457 −0.3091 0.3871 0.6783 −0.3697 0.2956 0.9608
40582444 ENSG00000206075 SERPINB5 −0.0545 0.8916 0.9457 −0.3333 0.3488 0.6783 −0.1030 0.7850 0.9608
40450700 ENSG00000012048 BRCA1 0.0424 0.9186 0.9457 0.2242 0.5367 0.7465 0.1879 0.6076 0.9608
41919949 ENSG00000164362 TERT 0.1515 0.6818 0.9457 0.2121 0.5599 0.7465 0.2242 0.5367 0.9608
42129390 ENSG00000161055 SCGB3A1 −0.0909 0.8114 0.9457 0.2606 0.4697 0.7226 0.0061 1.0000 1.0000
42042450 ENSG00000134982 APC 0.2000 0.5835 0.9457 −0.0909 0.8114 0.9311 0.1030 0.7850 0.9608
41919948 ENSG00000164362 TERT 0.0303 0.9457 0.9457 0.0909 0.8114 0.9311 0.1515 0.6818 0.9608
41919950 ENSG00000164362 TERT 0.2727 0.4483 0.9457 0.0788 0.8380 0.9311 0.1758 0.6320 0.9608
39692687 ENSG00000084207 GSTP1 0.2121 0.5599 0.9457 0.0182 0.9728 1.0000 0.0667 0.8648 0.9608
42129391 ENSG00000161055 SCGB3A1 0.0909 0.8114 0.9457 0.0061 1.0000 1.0000 −0.0061 1.0000 1.0000
Table 4. Spearman correlation (ρ) of methylation degrees (log-cpm) and (a) genistein, (b) daidzein and (c) total 
isoflavone concentrations. Columns represent Map of the Human Methylome identifiers, Ensemble identifiers, 
Gene Symbol, Spearman correlation (ρ), P-value, and False Discovery Rate (FDR) for (a) genistein, (b) daidzein 
and (c) total isoflavone concentration.
GO Term Category
Number of genes 
for GO term
Number of 
DM genes P-value FDR
Vacuolar part CC 702 18 3.25E-06 0.068772
Vacuolar membrane CC 596 15 2.83E-05 0.291939
Vacuole CC 1184 22 4.14E-05 0.291939
Voltage-gated calcium channel activity involved in 
cardiac muscle cell action potential MF 5 2 0.000514 1
Transcriptional activator activity, RNA polymerase 
II distal enhancer sequence-specific binding MF 25 3 0.000763 1
L-type voltage-gated calcium channel complex CC 6 2 0.000768 1
Coreceptor activity involved in Wnt signaling 
pathway, planar cell polarity pathway MF 6 2 0.000768 1
Melanosome organization BP 26 3 0.000857 1
Pigment granule organization BP 27 3 0.000959 1
Lysosomal membrane CC 283 8 0.001081 1
Table 5. Top 10 results GO analysis for putatively differentially methylated regions (P < 0.0005). Columns 
represent Gene Ontology (GO) term, Category (being: CC: Cellular Component, MF: Molecular Function and 
BP: Biological Process), the number of genes in the gene set, the number of “differentially methylated” genes 
(loose P < 0.0005 cut-off), the P-value, and False Discovery Rate (FDR).
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JAK2 are described to be related to proliferation, survival and invasiveness of breast cancer20–23. Also, top KEGG 
pathway analysis results exhibit some pathways that have a known association to breast and other cancers such as 
mTOR, Oxytocine, MAPK, AGE-RAGE signaling pathways24–27. Yet, since both the differential methylation and 
pathway analyses yielded no significant results upon FDR correction, it is clear that these findings at most point 
towards the necessity of larger studies to identify possible minor or subpopulation specific effects and do not 
support major epigenetic modulation of breast cancer risk (positive or negative) as such.
Next to increasing power by larger sample numbers and a possible impact of duration of soy consumption, 
also the (variance of the) age of the participants should be considered in larger studies. In the study at hand, 
both control and treatment populations were very heterogeneous (Table 1), as we aimed to identify general (i.e. 
age-independent) methylation differences in the adult female population due to soy consumption. However, 
whereas our analyses indicate no large, age-independent differences in breast methylation, recent literature links 
the possible positive or negative effect of soy consumption on breast cancer risk in adults to the period or age when 
soy consumption started4,28. Early-life exposure to soy may alter estrogen mediated processes and therefore, alter 
the effect of genistein, daidzein and other isoflavones, which are estrogen antagonists. Whether this effect is sus-
tained by DNA methylation remains largely unknown28. Note that also other sources of heterogeneity (e.g. smok-
ing, contraceptive use, menstrual cycle) present in our study may obscure effects only present in specific subgroups.
In conclusion, in this exploratory analysis, we observed no impact of soymilk consumption on the human 
mammary gland epigenome. Furthermore, our study could not confirm previously described results of either 
in vivo or in vitro studies. Therefore, overall, our exploratory results do not support major general impact of 
short duration soymilk consumption on breast health through DNA methylation. Yet, we suggest that larger scale 
research with prolonged exposure and on different time points through female development, menstrual cycles 
and considering age, is essential for a full understanding of the impact of soy metabolites on (epigenetically reg-
ulated) breast health.
Materials and Methods
Subjects and treatments. A total of 30 generally healthy Belgian or Dutch women, scheduled for an aes-
thetic breast reduction, were recruited for this study; 20 of them were included in this epigenomics study. The 
exclusion criteria were breast cancer, antibiotic treatment within the previous month, and soy allergy. Ethical 
approval was granted by the Ethics Committee of the Ghent University Hospital (EC UZG 2005/022). The volun-
teers were fully informed of the aims of the study and gave their written consent. All experiments were performed 
in accordance with relevant local and national guidelines and regulations.
One batch of commercially available soymilk derived from whole soybeans in 250 mL cartons (Alpro® 
Soya Drink Nature, Alpro NV, Wevelgem, Belgium) was kindly provided by the manufacturer and analyzed in 
triplicate at study onset and closure as described by Bolca et al.29. One portion of soymilk (250 mL) contained 
16.98 ± 0.76 mg genistein and 5.40 ± 0.22 mg daidzein aglycone equivalents, and 8.25 g proteins, 7 g carbohy-
drates, 4.75 g lipids, 1.5 g fibers, 0.375 µg vitamin B12, 0.6 µg vitamin B2, and minerals.
Study design. This study was a randomized dietary intervention trial with a run-in phase of at least 4 days 
and a supplementation phase of 5 days before breast surgery. Following eligibility assessment, volunteers were 
randomly allocated to the soymilk (n = 10) or control (n = 20, of which 10 included in the epigenomics study) 
group. All participants were asked to abstain from soy-based products during the whole experimental period. A 
detailed list of isoflavone-containing foods and dietary supplements was distributed in order to guide the volun-
teers in this respect. Additionally, subjects were instructed to report every case of doubt or fortuitous consump-
tion and to provide detailed information on that eating occasion, including type and portion size. During the 
supplementation phase, 250 mL soymilk was consumed daily with breakfast, lunch, and dinner. The control group 
did not receive any supplementation before surgery. Compliance was evaluated by subject inquiry and urinary 
isoflavone excretion.
Subjects delivered a spot urine sample after the run-in phase and before anesthesia. During surgery (12–18 h 
after last soy supplementation), blood and breast biopsies were collected. Serum was obtained by centrifugation 
Pathway
Number of genes 
in pathway
Number of 
DM genes P-value FDR
mTOR signaling pathway 151 6 0.00076536 0.248742101
HTLV-I infection 255 7 0.00239934 0.375649312
Oxytocin signaling pathway 153 5 0.00502011 0.375649312
MAPK signaling pathway 295 7 0.00537556 0.375649312
AGE-RAGE signaling pathway in diabetic complications 99 4 0.00577922 0.375649312
Cholinergic synapse 112 4 0.00889251 0.469555659
Cortisol synthesis and secretion 63 3 0.01080852 0.469555659
Long-term potentiation 67 3 0.0127745 0.469555659
Autophagy - animal 128 4 0.01402011 0.469555659
Table 6. Top 10 results for pathway analysis for putatively differentially methylated regions (P < 0.0005). 
Columns represent KEGG pathway, the number of genes in a pathway, the number of “differentially methylated” 
genes (loose P < 0.0005 cut-off), the P-value, and False Discovery Rate (FDR).
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(10 min at 600 g, room temperature) after coagulation. Aliquots of both urine and serum samples were stored at 
−20 °C until analysis. The tissue samples were immediately frozen in liquid nitrogen and stored at −80 °C until 
analysis. Without thawing the tissue samples, fractions containing almost exclusively glandular tissue were dis-
sected, based on gross inspection. Areas of adipose tissue intimately intermixed with fibroglandular tissue were 
avoided and connective tissue was removed. Before processing, all samples were randomized and the investigators 
were blinded to the treatments when working with the samples.
In addition, a general questionnaire was used to obtain information on the subjects’ history of antibiotic 
treatments, hormonal therapies, other medication, food supplement intakes, and anthropometric measures. 
Each participant reported her habitual fat and fiber intakes, and her soy consumption since birth using validated 
self-administered food-frequency questionnaires30.
Chemicals. Genistein, daidzein, and equol were purchased from Extrasynthèse (Genay, France), and dihydro-
daidzein and O-desmethylangolensin from Plantech UK (Reading, UK). For the hydrolysis of conjugated isofla-
vones, a 33 g/L-solution of Type H-1 Helix pomatia extract (min. 300 U β-glucuronidase/mg and 15.3 U sulfatase/
mg; Sigma-Aldrich, Bornem, Belgium) in sodium acetate buffer (0.1 mol/L, pH = 5) was prepared. A 400 µmol/L 
and 40 µmol/L-solution of 4-hydroxybenzophenone in methanol was used as internal standard in the quantitative 
analyses of urine, serum, and breast tissue, respectively.
Exposure to isoflavones and 17β-estradiol. Genistein, daidzein, dihydrodaidzein, equol, and 
O-desmethylangolensin in urine were quantified upon enzymatic hydrolysis and liquid-liquid extraction, using 
a LC-MS method validated by Wyns et al.31. Based on a creatinine clearance rate of 0.163 mmol/(d.kg)32, daily 
urinary isoflavone excretions were calculated33. Quantification of genistein, daidzein, dihydrodaidzein, equol, 
O-desmethylangolensin, and the internal standard in hydrolyzed serum (200 µL) and glandular tissue (250 mg) 
was performed by LC-MS/MS according to Bolca et al.5.
Additionally, estrogens were extracted from glandular breast tissue (200 mg) as described by Chetrite et al.34 
and analyzed for 17β-estradiol using a quantitative immunoassay (EIA-4499, DRG Instruments GmbH, Marburg, 
Germany).
MethylCap-seq. High-quality genomic DNA (gDNA) (20–50 kb; 11.04–127.42 ng/mg) was obtained from 
22 mammary gland samples (10 soymilk, 10 matched controls, 2 technical replicates – one for each treatment 
group) using the PureLink Genomic DNA Mini kit (Invitrogen, Merelbeke, Belgium). Briefly, 50–85 mg of man-
ually dissected glandular tissue was lysed with proteinase K (20 g/L) for 4 h at 55 °C and 300 rpm. The lysate was 
centrifuged (3 min at 17968 g, room temperature) and treated with RNase A (20 g/L in 50 mM Tris-HCl (pH 8.0), 
10 mM EDTA; 2 min at room temperature). The sample was purified through a silica-based membrane and gDNA 
was eluted twice with 50 µL of water. DNA quantity and fragment length were measured using Qubit dsDNA HS 
assay (Invitrogen, Merelbeke, Belgium) and 1% agarose gelelectrophoresis, respectively, and all samples were 
diluted to a final concentration of 500 ng gDNA/75 µL water.
MethylCap-seq is a genome-wide DNA methylation profiling methodology combining methyl binding 
domain (MBD) based capture of methylated fragments and subsequent massive-parallel sequencing, also known 
as MBD-seq35–37. MethylCap-seq was performed by NXTGNT (Ghent, Belgium) as outlined earlier38, with follow-
ing modifications: (a) 500 ng input material was used for the affinity purification step (MethylCap kit, Diagenode, 
Liege, Belgium), (b) paired-end (2 × 51 nt, excluding adapters and multiplex identifiers) massive parallel sequenc-
ing was performed on the Illumina HiSeq2000 platform.
Global DNA methylation percentages. Global DNA methylation levels were assessed as previously 
reported39. As a minimum amount of 1 µg gDNA input was required, analyses were performed on the qualifying 
subset of 6 treatment and 5 control samples. In summary, gDNA was enzymatically hydrolyzed to deoxyribonu-
cleosides and dissolved in LC-grade water. Similarly, stock solutions were prepared for reference standards of 
2′-deoxycytidine (dC) and 5-methyl-2′-deoxycytidine (5-mdC), purchased from Sigma (D3897-1G) and Jena 
Bioscience (N-1044) respectively, to create a series of calibration standards, used in all of the experiments. Global 
DNA methylation was assessed by quantifying both 5-mdC and dC using Waters Acquity UPLC coupled to 
Waters Micromass Quattro Premier Mass Spectrometer (electrospray ionization in positive mode). Global DNA 
methylation was calculated as a percentage of 5-mdC versus the sum of 5-mdC and dC.
Data analysis. For MethylCap-seq, sequence reads were mapped to the human reference genome (GRCh37) 
with BOWTIE40 and aligned fragments were summarized using the in-house developed Map of the Human 
Methylome (http://www.biobix.be/map-of-the-human-methylome/). As previously described in e.g. Van Vlodrop 
et al.19, this map contains genomic regions that are putatively independently methylated, without relying on exist-
ing gene annotation. For each of these regions, the maximum number of mapped fragments (“peak height”) per 
sample was used for subsequent analysis (duplicate fragments removed). For annotation, we relied on Ensembl 
Genes 91. Unless mentioned otherwise, subsequent data analysis was performed using R (3.3.2)41.
For the exploratory analysis, the technical replicates were included and log-transformed counts per millions 
(log-cpm) values were calculated using the “cpm” function present in the R Bioconductor EdgeR package (version 
3.16.5)42. Subsequently, the 10,000 loci with most variance were selected for hierarchical clustering (“complete” 
method on Euclidean distance matrix, using the “hclust” function).
For the statistical assessment of differential methylation, those technical replicates with the lowest overall cov-
erage where removed from the analysis. Average log-cpm values were used to compare the genic-intergenic resp. 
promoter-genic methylation ratios between treatment groups. For the locus specific comparisons, only those loci 
featured by Gene Symbol annotation and an average coverage of at least 4 (prior to normalization) were used. This 
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filtering step, aiming to remove uninformative variables from the data set, together with the removal of duplicate 
entries led to a final set of 759,275 loci out of a total of 3,618,706.
For the analysis of differentially methylated loci, the limma-voom model was used43, since limma-voom pre-
sented considerably improved quality statistics compared to others (based on MA-plot and P-value distribution, 
data not shown). As is standard practice for limma-voom, TMM normalization (from EdgeR package) was per-
formed on the filtered counts42,44. Known to be often associated with gene expression, particularly promoter 
methylation is of interest, leading us to focus on the 49,378 promoter regions (2000 bp upstream to 500 bp down-
stream of canonical transcription start site, based on Ensembl annotation) for the promotor specific differential 
methylation analysis.
Gene Ontology (GO) enrichment analysis was performed using the “goana” function in the limma pack-
age. This package uses Entrez gene identifiers and can simultaneously report on the three main GO catego-
ries: biological processes, molecular functions and cellular components. For gene set analysis, a P-value cutoff 
(P-value < 0.0005) was used rather than a multiple testing adjusted cut-off given the general lack of significant 
results for the individual genes (see Results). Although individual loci considered are thus less reliable, this is 
putatively compensated by the higher number of actually differentially methylated loci, leading to increased 
power for the gene set analysis. Additionally, pathway analysis was investigated using the “kegga” function in 
the limma package. Cut-off criteria and P-value correction were performed analogously to the GO enrichment 
analysis.
LINE-1 methylation was evaluated by mapping (BOWTIE, loose parameter settings: L = 5, e = 100) both 
paired-end reads separately on the Homo Sapiens LINE-1 consensus sequence (L1HS) obtained from Repbase45 
and counting the mapped reads. Duplicate reads were removed first using FastUniq46. Paired-ends mapping both 
to L1HS were counted as a single event. L1HS count data were normalized for coverage differences by division by 
the total number of sequenced fragments.
Additional data analyses were performed in R (3.3.2) as well: the Student t-test was used to compare sequenc-
ing characteristics, LINE-1 methylation, and global DNA methylation between groups, the Wilcoxon rank-sum 
test for the comparison of 17β-estradiol concentration and both genic-intergenic and promoter-genic methyl-
ation ratios between treatment groups, and Spearman correlation to evaluate the correlation between isofla-
vone concentrations and library sizes resp. locus-specific methylation degrees. Throughout the manuscript, 
Benjamin-Hochberg P-value adjustment was performed to correct for multiple testing, leading to False Discovery 
Rate (FDR) estimates.
Data Availability
The datasets generated and analysed during the current study are available in the Gene Expression Omnibus 
(GEO) repository, GSE112727.
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